MUSTANG BIO INC (MBIO) Stock Price, Quote, News and Overview
NASDAQ:MBIO - Nasdaq - US62818Q3020 - Common Stock - Currency: USD
MBIO Quote, Performance and Key Statistics
1.24
+0.01 (+0.81%)
The current stock price of MBIO is 1.24 USD. In the past month the price decreased by -12.06%. In the past year, price decreased by -92.15%.
MBIO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.17 | 307.41B | ||
| AMGN | AMGEN INC | 14.05 | 149.68B | ||
| GILD | GILEAD SCIENCES INC | 22.89 | 131.53B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1691.28 | 126.09B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.83 | 64.01B | ||
| ARGX | ARGENX SE - ADR | 322.51 | 36.63B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.80B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.24B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.16B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.17B | ||
| NTRA | NATERA INC | N/A | 19.55B | ||
| BIIB | BIOGEN INC | 7.22 | 17.40B |
Related stock screener links
About MBIO
Company Profile
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the translation of medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. The company is headquartered in Worcester Massachusetts, Massachusetts and currently employs 80 full-time employees. The company went IPO on 2017-08-22. The firm has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR-T) therapies across multiple cancers, as well as lentiviral gene therapies for severe combined immunodeficiency. Its pipeline is focused in three core areas: CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors and gene therapies for rare genetic disorders. The company is developing a CAR T therapy for hematologic malignancies in partnership with Fred Hutch targeting CD20 (MB-106). In partnership with St. Jude, its X-linked Severe Combined Immunodeficiency (XSCID) gene therapy programs (MB-117 and MB-217) are being developed under an exclusive license to develop a potentially curative treatment for XSCID, a rare genetic immune system condition.
Company Info
MUSTANG BIO INC
377 Plantation Street
Worcester Massachusetts MASSACHUSETTS 01605 US
CEO: Manuel Litchman
Employees: 80
Company Website: https://www.mustangbio.com/
Investor Relations: https://ir.mustangbio.com/
Phone: 17816524500
MUSTANG BIO INC / MBIO FAQ
What is the stock price of MUSTANG BIO INC today?
The current stock price of MBIO is 1.24 USD. The price increased by 0.81% in the last trading session.
What is the ticker symbol for MUSTANG BIO INC stock?
The exchange symbol of MUSTANG BIO INC is MBIO and it is listed on the Nasdaq exchange.
On which exchange is MBIO stock listed?
MBIO stock is listed on the Nasdaq exchange.
What is MUSTANG BIO INC worth?
MUSTANG BIO INC (MBIO) has a market capitalization of 4.10M USD. This makes MBIO a Nano Cap stock.
How many employees does MUSTANG BIO INC have?
MUSTANG BIO INC (MBIO) currently has 80 employees.
What are the support and resistance levels for MUSTANG BIO INC (MBIO) stock?
MUSTANG BIO INC (MBIO) has a support level at 1.21 and a resistance level at 1.32. Check the full technical report for a detailed analysis of MBIO support and resistance levels.
Should I buy MUSTANG BIO INC (MBIO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MBIO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MBIO, evaluating the profitability, health, valuation and growth aspects
- MUSTANG BIO INC (MBIO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MUSTANG BIO INC (MBIO) Sales and EPS estimates to see what analysts future expectations are.
- MUSTANG BIO INC (MBIO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MUSTANG BIO INC (MBIO) Insider and Institutional Ownership to learn about the owners and their transactions.
- MUSTANG BIO INC (MBIO) Stock Chart to make your own analysis
- MUSTANG BIO INC (MBIO) Latest news and press-releases to stay up to date.
Does MUSTANG BIO INC (MBIO) stock pay dividends?
MBIO does not pay a dividend.
When does MUSTANG BIO INC (MBIO) report earnings?
MUSTANG BIO INC (MBIO) will report earnings on 2025-05-13.
What is the Price/Earnings (PE) ratio of MUSTANG BIO INC (MBIO)?
MUSTANG BIO INC (MBIO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.32).
What is the Short Interest ratio of MUSTANG BIO INC (MBIO) stock?
The outstanding short interest for MUSTANG BIO INC (MBIO) is 5.49% of its float. Check the ownership tab for more information on the MBIO short interest.
MBIO Technical Analysis
MBIO Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to MBIO. Both the profitability and financial health of MBIO have multiple concerns.
MBIO Financial Highlights
Over the last trailing twelve months MBIO reported a non-GAAP Earnings per Share(EPS) of -6.32. The EPS increased by 43.82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -169.23% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
MBIO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to MBIO. The Buy consensus is the average rating of analysts ratings from 7 analysts.